Bruker Corporation
BRKRHealthcareNASDAQMedical Devices · Last scanned Sep 7, 2026
Scan Results
Daily timeframePart of the healthcare sector, Bruker Corporation (BRKR) is listed under Medical Devices. The $8.91B market capitalization puts BRKR squarely in mid-cap range for its industry. It operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.
Market Cap
$8.91B
Beta
1.26
P/E (TTM)
—
P/E (Fwd)
24.31
EPS (TTM)
$-0.70
EPS (Fwd)
$2.41
ROE
-3.0%
ROA
3.1%
Cash
$184.9M
Total Debt
$1.86B
Free CF
$179.9M
52W Change
89.9%
Annual Financials
Cash vs Debt
Where BRKR stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, BRKR finished 23.50% above its 150-day moving average ($47.79) and 23.50% above its 200-day moving average ($47.79). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is BRKR overbought or oversold?
At the September 3, 2026 close, BRKR's RSI(14) was 53.1, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The company holds $184.9M in cash, though total debt stands at $1.86B. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Free cash flow comes in at $179.9M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. Return on equity stands at -3.0%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. ROA of 3.1% is on the lower side, which is common in asset-heavy industries. Revenue has grown from $2.53B (2022) to $3.44B (2025), reflecting a 36% increase over the period.
Bruker Corporation carries a heavier debt load relative to its cash position, which introduces financial risk that investors should weigh. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Bruker Corporation's trajectory.